Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trained nnU-Net model for semantic segmentation of human adult cervical vertebrae from CT-Scans.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2025
Same author

Introducing article numbering to JournaldeMycologieMédicale.

Journal de mycologie medicale·2020
Same author

[Feasibility and benefits of training to screen for chronic obstructive pulmonary disease].

Revue des maladies respiratoires·2019
Same author

[Lower extremity arteriopathy disease in the elderly: A systematic review].

Annales de cardiologie et d'angeiologie·2018
Same author

Optimal long-term antithrombotic treatment of patients with stable coronary artery disease and atrial fibrillation: "OLTAT registry".

International journal of cardiology·2018
Same author

[The Revue becomes Journal of Stomatology Oral and Maxillofacial Surgery].

Revue de stomatologie, de chirurgie maxillo-faciale et de chirurgie orale·2016
Same journal

[Study of Sleep Apnea Syndrome in Patients with Chronic Heart Failure in the Cardiology Department at Yalgado Ouédraogo teaching hospital in 2024 and 2025].

Annales de cardiologie et d'angeiologie·2026
Same journal

[Impact of knowledge and practices of hygieno-dietetical measures in hypertensive people at the Abidjan cardiology institute].

Annales de cardiologie et d'angeiologie·2026
Same journal

[Correlation between carotid atheroma and DAS28 gamma GT score in rheumatoid arthritis in an African black population].

Annales de cardiologie et d'angeiologie·2026
Same journal

[Dobutamine stress echocardiography: Appropriateness of indications and protocol compliance. A single-centre report].

Annales de cardiologie et d'angeiologie·2026
Same journal

[Post-COVID postural orthostatic tachycardia syndrome: Documentation of a hyperadrenergic phenotype by comprehensive autonomic testing].

Annales de cardiologie et d'angeiologie·2026
Same journal

Urban-rural disparities in hypertension prevalence, screening, and control in South Kivu Province, eastern Democratic Republic of the Congo.

Annales de cardiologie et d'angeiologie·2026
See all related articles

Related Experiment Videos

[What's new on antithrombotics?].

G Helft1, P Leger

  • 1Institut de cardiologie, hôpital Pitié-Salpêtrière, AP-HP, 47, boulevard de l'Hôpital, 75013 Paris, France. gerard.helft@psl.aphp.fr

Annales De Cardiologie Et D'Angeiologie
|October 28, 2008
PubMed
Summary
This summary is machine-generated.

New anticoagulant drugs offer improved venous thromboembolism treatment with reduced bleeding risk and no need for regular monitoring. Research evaluates extended treatment durations and new agents like dabigatran etexilate for prophylaxis and acute coronary syndromes.

Related Experiment Videos

Area of Science:

  • Cardiology and Pharmacology
  • Thrombosis and Hemostasis

Context:

  • Venous thromboembolism (VTE) management requires safer, more effective anticoagulants.
  • Current treatments like coumarins necessitate regular monitoring.
  • Advancements in antithrombotic therapies are crucial for improving patient outcomes.

Purpose:

  • To review new anticoagulant drugs and their efficacy in VTE treatment and prophylaxis.
  • To assess the role of novel agents like idraparinux, dabigatran etexilate, bivalirudin, fondaparinux, and prasugrel.
  • To evaluate the impact of recent guidelines and trials on antithrombotic drug selection.

Summary:

  • Idraparinux, an anti-Xa inhibitor, is compared to coumarins for VTE treatment.
  • Dabigatran etexilate, a direct thrombin inhibitor, shows efficacy in VTE prophylaxis post-hip replacement.
  • New European guidelines incorporate bivalirudin and fondaparinux for non-ST-segment elevation acute coronary syndromes (NSTE-ACS).
  • Prasugrel demonstrates reduced ischemic events but increased bleeding in PCI-treated patients with SCA.
  • Drug-eluting stents (DES) show tempered concerns regarding mortality.

Impact:

  • Novel anticoagulants may reduce bleeding complications and monitoring needs in VTE management.
  • New drugs offer alternative or adjunctive therapies for acute coronary syndromes and post-surgical prophylaxis.
  • Ongoing research and updated guidelines will shape future antithrombotic treatment strategies.